Neuland Laboratories Limited - Asset Resilience Ratio
Neuland Laboratories Limited (NEULANDLAB) has an Asset Resilience Ratio of 6.06% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Neuland Laboratories Limited debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how Neuland Laboratories Limited's Asset Resilience Ratio has changed over time. See what is Neuland Laboratories Limited's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Neuland Laboratories Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see NEULANDLAB stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs152.21 Million | 0.6% |
| Short-term Investments | Rs1.38 Billion | 5.46% |
| Total Liquid Assets | Rs1.54 Billion | 6.06% |
Asset Resilience Insights
- Limited Liquidity: Neuland Laboratories Limited maintains only 6.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Neuland Laboratories Limited Industry Peers by Asset Resilience Ratio
Compare Neuland Laboratories Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Neuland Laboratories Limited (2006–2025)
The table below shows the annual Asset Resilience Ratio data for Neuland Laboratories Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 13.64% | Rs2.97 Billion ≈ $32.17 Million |
Rs21.80 Billion ≈ $235.75 Million |
+8.62pp |
| 2024-03-31 | 5.02% | Rs920.70 Million ≈ $9.96 Million |
Rs18.33 Billion ≈ $198.18 Million |
+3.30pp |
| 2023-03-31 | 1.73% | Rs272.60 Million ≈ $2.95 Million |
Rs15.80 Billion ≈ $170.85 Million |
+1.48pp |
| 2022-03-31 | 0.24% | Rs33.77 Million ≈ $365.19K |
Rs13.83 Billion ≈ $149.62 Million |
-0.37pp |
| 2021-03-31 | 0.61% | Rs81.16 Million ≈ $877.68K |
Rs13.25 Billion ≈ $143.27 Million |
+0.00pp |
| 2020-03-31 | 0.61% | Rs75.00 Million ≈ $811.10K |
Rs12.31 Billion ≈ $133.13 Million |
-0.05pp |
| 2019-03-31 | 0.66% | Rs75.00 Million ≈ $811.10K |
Rs11.30 Billion ≈ $122.24 Million |
-0.04pp |
| 2018-03-31 | 0.70% | Rs75.00 Million ≈ $811.10K |
Rs10.71 Billion ≈ $115.87 Million |
-1.16pp |
| 2017-03-31 | 1.86% | Rs164.65 Million ≈ $1.78 Million |
Rs8.86 Billion ≈ $95.77 Million |
+0.43pp |
| 2016-03-31 | 1.42% | Rs74.68 Million ≈ $807.59K |
Rs5.24 Billion ≈ $56.67 Million |
+1.42pp |
| 2013-03-31 | 0.00% | Rs2.00K ≈ $21.63 |
Rs4.25 Billion ≈ $45.96 Million |
+1.29pp |
| 2012-03-31 | -1.29% | Rs-55.04 Million ≈ $-595.24K |
Rs4.26 Billion ≈ $46.06 Million |
-3.65pp |
| 2011-03-31 | 2.36% | Rs100.38 Million ≈ $1.09 Million |
Rs4.26 Billion ≈ $46.07 Million |
-0.01pp |
| 2008-03-31 | 2.37% | Rs68.99 Million ≈ $746.10K |
Rs2.91 Billion ≈ $31.50 Million |
-1.50pp |
| 2007-03-31 | 3.87% | Rs77.11 Million ≈ $833.92K |
Rs1.99 Billion ≈ $21.57 Million |
+0.50pp |
| 2006-03-31 | 3.37% | Rs49.63 Million ≈ $536.74K |
Rs1.47 Billion ≈ $15.92 Million |
-- |
About Neuland Laboratories Limited
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.